March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. Photo via Getty Images

An emerging biotech company in Houston has closed its series A with outsized success.

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. The company has now raised more than $51 million in total.

Last year, March Biosciences announced its strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. CEO Sarah Hein met her co-founder, Max Mamonkin, at the TMC Accelerator for Cancer Therapeutics. Along with fellow co-founder Malcolm Brenner, March Biosciences launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital). Its goal is to fight cancers that have been unresponsive to existing immunotherapies using its lead asset, MB-105.

An autologous CD5-targeted CAR-T cell therapy, MB-105 is currently in phase-1 trials in patients with refractory T-cell lymphoma and leukemia. The treatment is showing signs of being both safe and effective, meriting a phase-2 trial that will begin early next year. The funds raised from the series A will help to finance the Phase 2 clinical development of MB-105 to expand on the existing data with optimized manufacturing processes.

“This oversubscribed financing enables us to advance our first-in-class CAR-T therapy, MB-105, into a Phase 2 trial for T-cell lymphoma – an indication with an exceptionally poor prognosis and few treatment options,” says Hein. “With the support and confidence of our investors, we are not only advancing our lead program but also expanding our pipeline, underscoring our commitment to delivering best-in-class therapies to patients that can change the treatment paradigm for these challenging cancers.”

But that’s not the only exciting news that Hein and her associates have to report. March Biosciences has recently partnered with cell therapy venture studio, Volnay Therapeutics. Led by highly experienced cell therapy development veterans, the March Biosciences team will work to develop a scalable manufacturing process for MB-105 that will lead to commercialization. Volnay co-founder and CEO Stefan Wildt, who held key R&D leadership positions in cell and gene therapy units at Novartis and Takeda, has also joined the board of March Biosciences. The board of directors is also welcoming Cassidy Blundell of Mission BioCapital and Owen Smith of 4BIO Capital.

“The team at March Biosciences is leveraging powerful science and promising clinical data to tackle cancers with significant unmet need,” says Blundell, a partner at Mission BioCapital. “We're excited to support their journey and believe their focused approach with MB-105 could lead to significant breakthroughs in the CAR-T space.”

The Houston-born company, which is a finalist for the 2024 Houston Innovation Awards, continues to accelerate quickly, in part thanks to its home base. After all, existing local investors like TMC Venture Fund also participated in the new raise. As Hein said last year, “Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

Rice biochemist Natasha Kirienko and MD Anderson physician-scientist Marina Konopleva made the striking discovery. Photo by Jeff Fitlow

Rice and MD Anderson researchers discover exciting new leukemia treatment

big win

Rice University and MD Anderson researchers have just discovered a potential one-two punch that could, they hope, knock out an insidious disease.

A recent study in the journal Leukemia centers on potential new drugs that, with the help of other medications, can thwart leukemia cells.

Specifically, Rice biochemist Natasha Kirienko and MD Anderson physician-scientist Marina Konopleva screened some 45,000 small-molecule compounds to find a few that targeted mitochondria, according to Rice press materials.

In this innovative new study, the team selected eight of the most promising compounds, identified between five and 30 closely related analogs for each, and conducted tens of thousands of tests to systematically determine how toxic each analog was to leukemia cells. This was measured both when administered individually or in combination with existing chemotherapy drugs like doxorubicin, notes a release.

Previously, Kirienko’s lab had shown the eight compounds targeted energy-producing machinery inside cells called mitochondria. Mitochondria, which work nonstop in every living cell, wear out with use. The chosen eight compounds induce mitophagy, which can be described as how cells decommission and recycle deficient and used-up.

Notably, during times of extreme stress, cells can temporarily forgo mitophagy for an emergency energy boost. Previous research has shown leukemia cells have far more damaged mitochondria than healthy cells and are also more sensitive to mitochondrial damage than healthy cells.

Thus, Kirienko and Konopleva reasoned that mitophagy-inducing drugs might weaken leukemia cells and make them more susceptible to chemotherapy. Synergy — using two or more drugs in treatment — is key.

“The point of synergy is that there are concentrations, or dosages, where a single drug doesn't kill,” Kirienko said. “There is no death of healthy cells or cancer cells. But administering those same concentrations in combination can kill a considerable amount of cancer cells and still not affect healthy cells.”

The team tested the toxicity of its mitophagy-inducing compounds and combinations against acute myeloid leukemia (AML) cells, the most commonly diagnosed form of the disease. They then tested the six most effective AML-killing compounds against other forms of leukemia, finding that five were also effective at killing acute lymphoblastic leukemia (ALL) cells and chronic myelogenous leukemia (CML) cells.

Studies found all the mitophagy-inducing drugs caused far less harm to healthy cells.

Finally, the researchers tested one of the most effective mitochondria-targeting compounds, PS127E, using a cutting-edge technique called a patient-derived xenograft (PDX) model. Also referred to as a “mouse clinical trial,” mice are implanted with cancer cells from a leukemia patient. As the cells grow, the mouse is exposed to a drug or combination of drugs as a closer-than-cells test of the treatment’s effect.

Importantly, PDX tests on one compound, PS127E, showed it was effective at killing AML cells in mice, Rice notes, signaling promising news.

“Although this is very promising, we’re still some distance from having a new treatment we can use in the clinic,” Kirienko added. “We still have a lot to discover. For example, we need to better understand how the drugs work in cells. We need to refine the dose we think would be best, and perhaps most importantly, we need to test on a wide variety of AML cancers. AML has a lot of variations, and we need to know which patients are most likely to benefit from this treatment and which are not. Only after we’ve done that work, which may take a few years, would we be able to start testing in humans.”

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

5 Houston female founders land on coveted Inc. 500 list

girl power

Five Houston female founders have been recognized by Inc. Magazine for their innovations and for leading their industries forward.

The women were named to Inc.'s Female Founders 500 list, which features female entrepreneurs based in the U.S. The group attracted approximately $9 billion in 2024 revenue and $10.6 billion in funding, according to Inc.

“Female founders know what struggle is, but they’re also experts of improvisation, adaptability, and creativity. The women featured on this year’s list exemplify these qualities," Diana Ransom, Inc. executive editor said in a release. "Through times of uncertainty, their unwavering dedication and steadfast leadership are not only inspiring but vital to driving progress.”

The Houston founders are:

  • Emily Cisek, founder of The Postage, now known as Paige, a comprehensive life planning and succession software platform for families and small businesses. The company won the Female-Owned Business category in the 2023 Houston Innovation Awards.
  • Sassie Duggleby, CEO and co-founder of Houston space tech and engine company Venus Aerospace. The company won the in the Deep Tech Business category in the 2024 Houston Innovation Awards. Duggleby also serves on the Texas Space Commission board of directors.
  • Stephanie Murphy, CEO and executive chairman of Aegis Aerospace, which provides space services, spaceflight product development, and engineering services. Murphy also serves on the Texas Aerospace Research and Space Economy Consortium Executive Committee.
  • Margo Jordan, founder of adolescent mental health startup Enrichly, which uses AI-driven self-esteem development and behavioral insights to boost student performance.
  • Nina Magon, founder of Nina Magon Studio / Nina Magon Consumer Products, a residential and commercial interior design company

"With every family and community we're able to impact through accessible estate planning, we're driven to do even more. Being recognized on Inc.’s Female Founders list is an incredible honor and a testament to the impact we’re making in fintech and beyond," Cisek said in a news release.

Duggleby echoed that sentiment on LinkedIn.

"While I don't know many of the ladies on this list, I do know they're some of the most tenacious role models in entrepreneurship. I'm beyond honored to be included among them," Duggleby added in a post.

Twenty-eight Texas female founders made this list, including Kendra Scott and Allison Ellsworth, co-founder of Poppi, and many others. See the full list of winners here.

Tesla forced to recall nearly all Cybertrucks in latest setback

Tesla Talk

U.S. safety regulators on Thursday recalled virtually all Cybertrucks on the road, the eighth recall of the Tesla-made vehicles since deliveries to customers began just over a year ago.

The National Highway Traffic Safety Administration's recall, which covers more than 46,000 Cybertrucks, warned that an exterior panel that runs along the left and right side of the windshield can detach while driving, creating a dangerous road hazard for other drivers, increasing the risk of a crash.

The stainless steel strip, called a cant rail assembly, between the windshield and the roof on both sides, is bound to the truck’s assembly with a structural adhesive, the NHTSA report said. The remedy uses an adhesive that’s not been found to be vulnerable to “environmental embrittlement,” the NHTSA said, and includes additional reinforcements.

Tesla will replace the panel free of charge. Owner notification letters are expected to be mailed May 19, 2025.

The recall of 46,096 Cybertrucks covers all 2024 and 2025 model years, manufactured from November 13, 2023, to February 27, 2025. The NHTSA order says that Tesla became aware of the problem early this year.

Videos posted on social media showing people ripping the panels off of Cybertrucks with their hands have gone viral in recent days.

The Cybertruck, which Tesla began delivering to buyers in late 2023, has been recalled eight times in the past 15 months for safety problems, including once in November because a fault in an electric inverter can cause the drive wheels to lose power. Last April, the futuristic-looking trucks were recalled to fix acceleration pedals that can get stuck in the interior trim. Other recalls were related to windshield wipers and the display screen.

It's the latest setback for the Elon Musk-owned electric automaker, which has come under attack since President Donald Trump took office and empowered Musk to oversee a new Department of Government Efficiency that’s slashing government spending.

While no injuries have been reported, Tesla showrooms, vehicle lots, charging stations and privately owned cars have been targeted.

Prosecutors in Colorado charged a woman last month in connection with attacks on Tesla dealerships, including Molotov cocktails thrown at vehicles and the words “Nazi cars” spray-painted on a building.

And federal agents in South Carolina last week arrested a man they say set fire to Tesla charging stations near Charleston. An agent from the Bureau of Alcohol, Tobacco, Firearms and Explosives wrote in an affidavit that authorities found writings critical of the government and DOGE in his bedroom and wallet.

Even before the attacks ramped up in recent weeks, Tesla has been struggling, facing increased competition from rival electric vehicles, particularly out of China.

Though largely unaffected by Thursday's recall announcement, Tesla shares have plummeted 42% in 2025, reflecting newfound pessimism as sales crater around the globe.

With regard to Thursday's recall, Cybertruck owners may contact Tesla customer service at 1-877-798-3752 and the National Highway Traffic Safety Administration Vehicle Safety Hotline at 888-327-4236, or go to nhtsa.gov.

$100,000 salary goes further in Houston than most cities, study shows

Cashing In

Even with Houston's ever-changing cost of living, earning a six-figure salary in the city is going much further than it used to, according to an income study by fintech company SmartAsset.

An annual $100,000 salary in Houston is worth $83,343 after taxes and when adjusted for the city's cost of living, the report revealed. That's $5,254 more than what six-figure-earning Houstonians were bringing home last year, a separate report from GoBankingRates.com found.

In SmartAsset's rankings of U.S. cities where $100,000 is worth the most, Houston ranked ninth.

The report warns a six-figure salary may seem comfortable at first, but it may not stretch as far depending on where an individual lives, any applicable tax obligations, and the rate of inflation.

"Earning $100,000 places an individual tax filer at the upper limit of the 22 percent federal tax bracket," the report's author wrote. "But taxes aren’t the only factor. The cost of living varies widely across the country, affecting how much purchasing power remains after necessary expenses."

Manhattan, New York is the No. 1 place where a six-figure salary is worth the least, where a New Yorker's take-home pay is only worth $30,362 after taxes and adjusted for the cost of living.

Other U.S. cities where a $100,000 salary goes the furthest
The U.S. city where a six-figure salary goes the furthest is Oklahoma City, where residents come away with $89,989 after all expenses.

Texas cities dominated the top 10 list. Texas doesn't impose state or local income taxes, which likely boosted its statewide six-figure salary value.

Six-figure earners living in El Paso see the greatest amount in take-home pay statewide, according to SmartAsset, with residents making $89,114 annually after taxes and expenses in 2025. That's $274 more than 2024's take-home pay.

The three additional Texas cities where a $100,000 salary goes the furthest after taxes and expenses are:

  • No. 3 – Corpus Christi ($88,015)
  • No. 6 – Lubbock ($86,846)
  • No. 7 – San Antonio ($86,084)

Six-figure salaries don't stretch as far in Dallas-Fort Worth. An annual $100,000 salary in Dallas is worth only $77,197 after taxes and expenses, which is about $900 less than what six-figure-earning Dallasites brought home in 2024.

Those living in Plano are taking home even less: The study says a Plano resident's six-figure salary is only worth $71,372 in 2025.

In the report's rankings of U.S. cities where $100,000 is worth the least, Plano ranked at No. 26, while Dallas ranked 38th.

SmartAsset used its paycheck calculator to apply federal, state and local taxes to an annual salary of $100,000 in 69 of the largest American cities, which was then adjusted for the local cost of living (which included average costs for housing, groceries, utilities, transportation, and miscellaneous goods and services).

---

A version of this story originally appeared on sister site, CultureMap.com.